Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
ACRS Analyst Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ACRS Stock 12 Month Forecast
Average Price Target
$7.92
▲(323.53% Upside)
| Highest Price Target$16.00 | Average Price Target$7.92 | Lowest Price Target$1.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$1.5
Hold
-19.79%
Downside
Reiterated
08/14/25
Leerink Partners
$7
Buy
274.33%
Upside
Reiterated
08/07/25
Analysts Are Bullish on Top Healthcare Stocks: Privia Health Group (PRVA), Aclaris Therapeutics (ACRS)We see both assets as partially de-risked based on (1) initial proof-of-concept data from a prior Phase 2a trial of bosa in AD, showing deep and durable responses in an open-label setting in the U.S., and (2) preclinical data for ATI-052, which suggests the potential for enhanced efficacy with this bispecific approach vs. conventional antibodies. Topline data from a randomized, placebo-controlled Phase 2 study for bosa in AD patients are expected in 2H26, while initial topline SAD/MAD data in healthy volunteers are expected for ‘052 in early 2026 – see our note HERE for more details. Lastly, we note that ACRS is planning an R&D event in October 2025, where we could see further details from Phase 2 China studies for bosa in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), as well as refined clinical plans across the company’s pipeline.
Wedbush
$8
Buy
327.81%
Upside
Reiterated
07/30/25
Scotiabank
$9
Buy
381.28%
Upside
Reiterated
07/30/25
Piper Sandler
$6
Buy
220.86%
Upside
Initiated
07/10/25
H.C. Wainwright
$16
Buy
755.61%
Upside
Reiterated
06/25/25
Jefferies
$7
Buy
274.33%
Upside
Reiterated
04/24/25
Cantor Fitzgerald
―
Buy
―
Initiated
03/18/25
Stifel Nicolaus
$5→$2
Hold
6.95%
Upside
Reiterated
03/03/25
BTIG
$8
Buy
327.81%
Upside
Upgraded
11/18/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$1.5
Hold
-19.79%
Downside
Reiterated
08/14/25
Leerink Partners
$7
Buy
274.33%
Upside
Reiterated
08/07/25
Analysts Are Bullish on Top Healthcare Stocks: Privia Health Group (PRVA), Aclaris Therapeutics (ACRS)We see both assets as partially de-risked based on (1) initial proof-of-concept data from a prior Phase 2a trial of bosa in AD, showing deep and durable responses in an open-label setting in the U.S., and (2) preclinical data for ATI-052, which suggests the potential for enhanced efficacy with this bispecific approach vs. conventional antibodies. Topline data from a randomized, placebo-controlled Phase 2 study for bosa in AD patients are expected in 2H26, while initial topline SAD/MAD data in healthy volunteers are expected for ‘052 in early 2026 – see our note HERE for more details. Lastly, we note that ACRS is planning an R&D event in October 2025, where we could see further details from Phase 2 China studies for bosa in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), as well as refined clinical plans across the company’s pipeline.
Wedbush
$8
Buy
327.81%
Upside
Reiterated
07/30/25
Scotiabank
$9
Buy
381.28%
Upside
Reiterated
07/30/25
Piper Sandler
$6
Buy
220.86%
Upside
Initiated
07/10/25
H.C. Wainwright
$16
Buy
755.61%
Upside
Reiterated
06/25/25
Jefferies
$7
Buy
274.33%
Upside
Reiterated
04/24/25
Cantor Fitzgerald
―
Buy
―
Initiated
03/18/25
Stifel Nicolaus
$5→$2
Hold
6.95%
Upside
Reiterated
03/03/25
BTIG
$8
Buy
327.81%
Upside
Upgraded
11/18/24
Best Analysts Covering Aclaris Therapeutics
1 Month
xxx
Success Rate
8/14 ratings generated profit
Average Return
-1.67%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of -1.67% per trade.
3 Months
xxx
Success Rate
7/14 ratings generated profit
Average Return
-12.07%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -12.07% per trade.
1 Year
Success Rate
4/14 ratings generated profit
Average Return
-36.78%
reiterated a buy rating 19 days ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -36.78% per trade.
2 Years
xxx
Success Rate
8/14 ratings generated profit
Average Return
+117.79%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +117.79% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ACRS Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
6
9
12
9
Buy
1
1
0
0
0
Hold
3
3
1
0
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
10
10
12
11
Each month's total comprises the sum of three months' worth of ratings.
ACRS Financial Forecast
ACRS Stock Forecast FAQ
What is ACRS’s average 12-month price target, according to analysts?
Based on analyst ratings, Aclaris Therapeutics’s 12-month average price target is 7.92.
What is ACRS’s upside potential, based on the analysts’ average price target?
Aclaris Therapeutics has 323.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACRS a Buy, Sell or Hold?
Aclaris Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
What is Aclaris Therapeutics’s price target?
The average price target for Aclaris Therapeutics is 7.92. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $1.50. The average price target represents 323.53% Increase from the current price of $1.87.
The highest analyst price target is $16.00 ,the lowest forecast is $1.50. The average price target represents 323.53% Increase from the current price of $1.87.
What do analysts say about Aclaris Therapeutics?
Aclaris Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of ACRS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.